In order to obtain further insight into the possible consequences of long-term administration of sunitinib or other TKIs to the sensitivity of tumor cells to second line therapy, we explored the resistance and cross-resistance patterns of tumor cells to several multi-targeted TKIs and the mTOR inhibitor everolimus. This evidence concerns the gene MTOR and neoplasm.